Shares of Obseva SA (NASDAQ:OBSV) have earned an average rating of “Buy” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $28.50.
A number of equities analysts recently commented on the company. HC Wainwright set a $30.00 price objective on Obseva and gave the stock a “buy” rating in a report on Wednesday, July 25th. Zacks Investment Research downgraded Obseva from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Leerink Swann assumed coverage on Obseva in a report on Wednesday, August 15th. They issued an “outperform” rating and a $25.00 price objective on the stock. Credit Suisse Group assumed coverage on Obseva in a report on Thursday, July 19th. They issued an “outperform” rating and a $24.00 price objective on the stock. Finally, Wedbush assumed coverage on Obseva in a report on Monday, August 6th. They issued an “outperform” rating and a $34.00 price objective on the stock.
Hedge funds have recently made changes to their positions in the business. US Bancorp DE acquired a new position in Obseva during the second quarter valued at approximately $197,000. Tiverton Asset Management LLC acquired a new position in Obseva during the second quarter valued at approximately $224,000. Jane Street Group LLC acquired a new position in Obseva during the second quarter valued at approximately $349,000. DRW Securities LLC grew its holdings in Obseva by 55.0% during the second quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock valued at $512,000 after purchasing an additional 12,000 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Obseva during the second quarter valued at approximately $519,000. Institutional investors own 68.26% of the company’s stock.
Obseva (NASDAQ:OBSV) last issued its earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05. Sell-side analysts forecast that Obseva will post -1.93 earnings per share for the current fiscal year.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
See Also: What Does Beta Mean In Stock Selection
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.